FDA orders Lilly post‑marketing studies
The FDA has required Eli Lilly to run post‑marketing studies for its newly approved oral obesity pill to monitor risks including liver injury, cardiovascular events, gastric emptying and effects on lactation. Those mandated studies move the obesity‑drug story from approval into an active safety and lifecycle phase that will influence coverage and utilisation. (reuters.com)
The Food and Drug Administration approved Eli Lilly’s obesity pill Foundayo on April 1, then ordered Lilly to run postmarketing studies tracking liver injury, heart risks, stomach-emptying problems and lactation effects. (fda.gov) (reuters.com) Foundayo is Lilly’s brand name for orforglipron, a once-daily glucagon-like peptide-1 pill for adults with obesity, or overweight with at least one weight-related medical problem. The Food and Drug Administration said the drug was approved 50 days after filing under its Commissioner’s National Priority Voucher pilot program. (fda.gov) (investor.lilly.com) Glucagon-like peptide-1 drugs mimic a gut hormone that helps people feel full and eat less. Foundayo’s selling point is convenience: Lilly said it can be taken any time of day, with or without food or water restrictions, unlike some older oral medicines. (investor.lilly.com) (pi.lilly.com) The new studies push the drug into the surveillance phase that follows approval, when regulators look for side effects that may be too rare, too delayed or too specific to show up clearly in preapproval trials. The Food and Drug Administration’s postmarketing database says these requirements cover clinical safety, efficacy, pharmacology and toxicology after a drug reaches the market. (fda.gov 1) (fda.gov 2) That matters in obesity medicine because use can spread quickly after launch, especially when a product is easier to take than an injection. Lilly said Foundayo prescriptions were accepted immediately after approval, with shipping beginning April 6 and broader retail pharmacy availability shortly after. (investor.lilly.com 1) (investor.lilly.com 2) Lilly said adults who stayed on the highest dose in the ATTAIN-1 trial lost an average of 27.3 pounds, or 12.4% of body weight, versus 2.2 pounds on placebo. The company also said the pill lowered several cardiovascular risk markers in the broader ATTAIN program. (investor.lilly.com) The approved label already carries a boxed warning about thyroid C-cell tumors seen in rodents and says the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The label also warns about pancreatitis, severe gastrointestinal reactions and kidney injury tied to volume depletion. (pi.lilly.com) Dosing starts at 0.8 milligrams once daily, rises to 2.5 milligrams after at least 30 days, then to 5.5 milligrams after another 30 days, with optional step-ups to 9, 14.5 and 17.2 milligrams. The label says Foundayo is not recommended in patients with severe gastroparesis, a condition in which the stomach empties too slowly. (fda.gov) (pi.lilly.com) The approval also gave Lilly a second Food and Drug Administration-cleared obesity medicine after Zepbound, its tirzepatide injection. The pill’s launch widens the race with Novo Nordisk, which has dominated the newer weight-loss market with injectable and oral glucagon-like peptide-1 products. (investor.lilly.com) (reuters.com) For now, Foundayo stays on the market while Lilly does the follow-up work the Food and Drug Administration demanded. Those studies will determine whether the pill’s first weeks as a fast-tracked approval become a longer test of how its risks look in wider use. (fda.gov) (reuters.com)
